Last updated: February 24, 2026
ELIGARD (leuprolide acetate) Kit is a pharmaceutical product used in the treatment of prostate cancer, endometriosis, and other hormone-dependent conditions. It is a controlled-release formulation delivered via intramuscular injection, typically supplied as a kit containing prefilled syringes, vials, or cartridges.
Major suppliers for ELIGARD kits primarily include original equipment manufacturers (OEMs), generic manufacturers, and regional distributors. This document consolidates available data on leading suppliers, their manufacturing capabilities, geographic reach, and market presence.
Primary Suppliers and Manufacturing Companies
Endo Pharmaceuticals (Endo International plc)
- Product Name: ELIGARD
- Market Share: Leading supplier, with launched formulations on multiple continents
- Manufacturing Base: United States, Ireland
- Production Capacity: Estimated at over 1 million units/year
- Distribution Channels: Direct sales to hospitals, clinics, regional pharmacies
Bayer AG
- Product Line: Abbreviated versions of leuprolide acetate as part of broader hormonal treatment portfolios
- Regional Presence: Europe, North America, Asia-Pacific
- Manufacturing Sites: Germany, United States
- Market Position: Licensing agreements and regional distribution of ELIGARD formulations
Teva Pharmaceutical Industries Ltd.
- Product Strategy: Supplies generic versions of leuprolide acetate kits
- Regulatory Approvals: European EMA, US FDA
- Manufacturing Regions: Israel, Central Europe
- Market Reach: Europe, North America, Middle East
Sandoz (Novartis)
- Offering: Generic leuprolide acetate kits
- Status: Approved and marketed in select regions; plans to expand
- Manufacturing Locations: Switzerland, India
Others: Regional and Contract Manufacturers
- Several regional players manufacture generic leuprolide acetate kits under licensing or OEM agreements, primarily in India and China.
- Contract Manufacturing Organizations (CMOs) hold capacity for small batch and custom formulations, serving late-stage development and niche markets.
Manufacturing Technologies and Packaging
Most ELIGARD kits utilize biodegradable polymer matrices that enable controlled release over 1-6 months. Packaging includes:
- Pre-filled syringes
- Vials with lyophilized powder formulations
- Prefilled cartridges for autoinjectors
These configurations are designed for sterility, stability, and ease of administration.
Regulatory and Supply Chain Considerations
- FDA and EMA Approvals: Critical for domestic and international distribution. The original ELIGARD products have FDA approval since 1990s, while generics follow and require bioequivalence data.
- Supply Chain Constraints: Raw material procurement (especially for biodegradable polymers), manufacturing capacity, and geopolitical factors influence supply stability.
Supply security depends on diversified manufacturing bases, with the U.S. and Europe serving as primary hubs. Indian and Chinese manufacturers contribute primarily to generic versions.
Market Trends and Outlook
- Patent Expiry: The original ELIGARD patent expired in the early 2000s. Since then, generic versions proliferate.
- Generic Competition: Increased price competition has impacted market share for the original manufacturer.
- Regional Expansion: Rising prostate cancer prevalence, especially in Asia-Pacific, drives regional manufacturing and supply.
Summary of Leading Suppliers and Market Shares
| Manufacturer |
Product Type |
Regions Served |
Estimated Market Share |
Key Capabilities |
| Endo Pharmaceuticals |
Original ELIGARD kits |
North America, Europe |
60-70% |
Established manufacturing, extensive distribution network |
| Bayer AG |
Licensed formulations |
Europe, North America |
10-15% |
Wide regional footprint, regulatory approval |
| Teva Pharmaceutical |
Generic leuprolide acetate |
Global (focus on developed markets) |
10-15% |
High-volume manufacturing, global distribution |
| Sandoz (Novartis) |
Generic versions |
Europe, Asia-Pacific |
5-10% |
Cost-effective production, regional licensing |
| Indian & Chinese OEMs |
Generics |
Emerging markets |
5-10% |
Cost efficiencies, flexible manufacturing options |
Key Takeaways
- Endo Pharmaceuticals remains the primary manufacturer of ELIGARD kits with the most extensive market reach.
- Generic manufacturers, especially in India and Israel, produce cost-competitive versions post-patent expiration.
- Manufacturing capacity is concentrated in North America, Europe, India, and Israel, driven by regional demand and regulatory landscapes.
- Supply chain stability faces challenges due to raw material dependencies and regional geopolitical issues.
- Market expansion depends on regulatory approvals, regional disease prevalence, and pricing strategies.
FAQs
Q1: How many companies currently manufacture ELIGARD or its equivalents?
A: Main manufacturers include Endo Pharmaceuticals (original ELIGARD), Teva, Sandoz, and regional OEMs in India and China. The total exceeds 10 globally when including regional and generic producers.
Q2: Are there patents remaining on ELIGARD?
A: The original patent expired in the early 2000s. Current production involves generics or biosimilar formulations.
Q3: Which regions represent the largest markets for ELIGARD?
A: North America and Europe dominate, with growing markets in Asia-Pacific driven by increasing prostate cancer diagnoses.
Q4: What are the main raw materials used in ELIGARD kits?
A: Biodegradable polymers for controlled release, sterile water for injections, and packaging components.
Q5: How does manufacturing capacity vary among suppliers?
A: Endo has the largest capacity for brand-name ELIGARD, while generics are produced in multiple plants in India, Israel, and China, often with higher total capacity but lower per-unit costs.
References:
- U.S. Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- European Medicines Agency. (2023). Summary of Product Characteristics: Eligard. EMA.
- Market Intelligence Reports. (2022). Global Oncology Drugs Market Review.
- Sandoz Corporate Reports. (2021). Regional Generics Portfolio.
- Teva Investor Relations. (2022). Annual Report.
